Alta Advisers Ltd Buys 7,916 Shares of Johnson & Johnson $JNJ

Key Points

• Alta Advisers increased its Johnson & Johnson stake by 84.5% in the third quarter, buying 7,916 shares and bringing its holding to 17,284 shares, valued at about $4.6 million.
• J&J reported quarterly earnings of $2.59 per share, beating estimates of $2.53, while revenue rose 5.9% year over year to $25.40 billion. The company set 2026 EPS guidance of $11.05–$11.15.
• Analysts give the stock a “Moderate Buy” consensus, with an average price target of $275.92. J&J also announced a quarterly dividend of $1.34 per share, equivalent to a 1.9% yield at the reported share price.

Alta Advisers Ltd increased its position in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 84.5% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 17,284 shares of the company's stock after purchasing an additional 7,916 shares during the quarter. Johnson & Johnson accounts for about 0.6% of Alta Advisers Ltd's investment portfolio, making the stock its 22nd largest holding. Alta Advisers Ltd's holdings in Johnson & Johnson were worth $4,576,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the stock. Outlook Capital Management LLC purchased a new stake in shares of Johnson & Johnson during the second quarter worth $28,000. Matrix Trust Co lifted its position in shares of Johnson & Johnson by 56.2% during the second quarter. Matrix Trust Co now owns 150 shares of the company's stock worth $38,000 after purchasing an additional 54 shares in the last quarter. Montgomery Financial Services LLC purchased a new stake in Johnson & Johnson in the 2nd quarter worth about $43,000. Hanseatic Management Services Inc. bought a new stake in Johnson & Johnson during the third quarter worth about $52,000. Finally, Polaris Financial Partners acquired a new stake in shares of Johnson & Johnson in the third quarter valued at about $56,000. Institutional investors own 69.55% of the company's stock.

Johnson & Johnson Price Performance

JNJ opened at $276.14 on Friday. The firm has a market capitalization of $664.76 billion, a PE ratio of 41.84, a price-to-earnings-growth ratio of 2.67 and a beta of 0.22. The company has a debt-to-equity ratio of 0.44, a current ratio of 1.02 and a quick ratio of 0.74. Johnson & Johnson has a 1 year low of $185.12 and a 1 year high of $282.02. The business's 50-day moving average is $265.91 and its two-hundred day moving average is $248.30.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last posted its earnings results on Tuesday, October 13th. The company reported $2.59 EPS for the quarter, topping the consensus estimate of $2.53 by $0.06. The firm had revenue of $25.40 billion during the quarter, compared to analysts' expectations of $25.38 billion. Johnson & Johnson had a net margin of 16.20% and a return on equity of 31.64%. Johnson & Johnson's quarterly revenue was up 5.9% on a year-over-year basis. During the same quarter in the prior year, the firm earned $2.80 EPS. Johnson & Johnson has set its FY 2026 guidance at 11.050-11.150 EPS. Research analysts anticipate that Johnson & Johnson will post 11.12 earnings per share for the current fiscal year.

Johnson & Johnson Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 8th. Stockholders of record on Tuesday, November 24th will be given a $1.34 dividend. The ex-dividend date of this dividend is Tuesday, November 24th. This represents a $5.36 dividend on an annualized basis and a dividend yield of 1.9%. Johnson & Johnson's payout ratio is currently 81.21%.

Wall Street Analysts Forecast Growth

Several equities analysts have recently commented on the stock. HSBC upped their price objective on shares of Johnson & Johnson from $290.00 to $320.00 and gave the company a "buy" rating in a research note on Thursday, September 10th. Guggenheim restated a "buy" rating and set a $287.00 target price on shares of Johnson & Johnson in a report on Wednesday, October 7th. Argus set a $300.00 price target on Johnson & Johnson in a research note on Wednesday, July 29th. Citigroup lifted their target price on shares of Johnson & Johnson from $298.00 to $303.00 and gave the stock a "buy" rating in a research note on Monday, October 5th. Finally, Morgan Stanley dropped their target price on Johnson & Johnson from $294.00 to $292.00 and set an "overweight" rating for the company in a report on Thursday, October 15th. One investment analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and eight have given a Hold rating to the company's stock. Based on data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average price target of $275.92.

Johnson & Johnson News Summary

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: The FDA granted accelerated approval to RYBREVANT FASPRO as a single-agent treatment for certain adults with recurrent or metastatic head and neck cancer after prior platinum chemotherapy and immunotherapy. J&J says the treatment is the first new option in this setting in a decade; trial data showed a 42% response rate. The approval extends the drug’s use beyond lung cancer and could broaden its commercial opportunity, though the indication is limited and accelerated approval may require confirmatory evidence. FDA approval announcement
• Positive Sentiment: J&J’s Innovative Medicine division grew third-quarter sales 7.7% to $16.76 billion, with established blockbusters and new launches more than offsetting generic competition. Continued growth despite patent-related headwinds supports the business outlook. Innovative Medicine sales report
• Neutral Sentiment: J&J was included in an article highlighting companies with a history of dividend increases and strong balance sheets. This reinforces its income-investor appeal, but the article does not identify a new company-specific dividend announcement. Dividend raisers article
• Negative Sentiment: Pomerantz LLP announced it is investigating potential claims on behalf of J&J investors. The notice does not provide details of the claims, but the investigation could add legal and reputational uncertainty. Investor investigation announcement

Insider Activity

In other news, EVP Jennifer Taubert sold 15,000 shares of the company's stock in a transaction dated Monday, August 17th. The stock was sold at an average price of $263.36, for a total value of $3,950,400.00. Following the completion of the sale, the executive vice president directly owned 194,451 shares of the company's stock, valued at $51,210,615.36. This represents a 7.16% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, EVP Timothy Schmid sold 33,597 shares of the company's stock in a transaction on Wednesday, September 2nd. The stock was sold at an average price of $274.74, for a total transaction of $9,230,439.78. Following the completion of the transaction, the executive vice president owned 25,447 shares of the company's stock, valued at $6,991,308.78. This trade represents a 56.90% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. 0.16% of the stock is currently owned by insiders.

Johnson & Johnson Profile

Johnson & Johnson is a global healthcare company that develops and sells prescription medicines and medical technologies. Its business is organized around two segments: Innovative Medicine and MedTech.

Innovative Medicine develops treatments in areas including oncology, immunology, neuroscience, cardiovascular and metabolic disease, and pulmonary hypertension. MedTech provides products and technologies for fields such as surgery, orthopedics, and vision care.

Founded in 1886, Johnson & Johnson serves patients and healthcare professionals in markets around the world.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.